Eli Lilly Moves to Enforce 340B Claims Data Reporting Compliance
Eli Lilly and Company (LLY) has announced a move to enforce compliance regarding 340B claims data reporting. This action focuses on ensuring adherence to regulations pertaining to the 340B drug pricing program.
Eli Lilly and Company (LLY), a major pharmaceutical firm, has announced its intention to enforce compliance concerning 340B claims data reporting. This initiative aims to ensure adherence to established regulations within the 340B drug pricing program.
The 340B program mandates that drug manufacturers provide outpatient drugs to eligible healthcare organizations and pharmacies at reduced prices. Ensuring proper data reporting is a critical component for the program's operational integrity and oversight.
According to Yahoo Finance, Eli Lilly is moving forward with these enforcement efforts.
Advertisement
AdSense slot • inline